176 results about "Antibiotic resistance" patented technology

This application relates to the field of food microbiology, and specifically discloses a Lactobacillus plantarum capable of producing 5-methyltetrahydrofolic acid, its fermentation method and application. A Lactobacillus plantarum inm30-LP capable of producing 5-methyltetrahydrofolic acid, with a preservation date of December 26, 2022, and the preservation unit is the General Microbiology Center of the China Committee for Culture Collection of Microorganisms, and the preservation number is CGMCC No. 26278. This application is based on the milk curd in the Gannan Tibetan area as the food source, isolates probiotics, and screens out Lactobacillus plantarum with high folic acid production from them. Moreover, the strain has obvious advantages over other lactic acid bacteria in terms of acid resistance and bile salt resistance, is suitable for growing in the gastrointestinal environment, has the ability to proliferate, has no antibiotic resistance, has antibacterial activity, and can produce bacteriocin.

The invention discloses nano-particles with antibacterial and osteogenesis promoting effects as well as a preparation method and application of the nano-particles, and belongs to the technical field of antibacterial nano-materials. On one hand, the invention provides the nano-particles with antibacterial and osteogenesis promoting effects and the preparation method thereof, and on the other hand, the invention provides the application of the nano-particles. The nanoparticles obtained by the method disclosed by the invention have good stability under physiological conditions (PH = 7.4); polyphenol, metal ions and AMP (adenosine monophosphate) can be slowly released in an inflammatory (weakly acidic) environment, and the functions including but not limited to bacterium capturing, bacterium killing, inflammation and oxidation resisting, osteogenesis promoting and the like are realized; the nano-particles can be used for preparing a bone infection treatment drug, and the bone infection treatment drug has a broad-spectrum antibacterial effect and cannot cause antibiotic drug resistance; the treatment medicine can efficiently prevent and treat bone infection and improve bone repair efficiency.

The present invention relates to the technical field of phages. Provided are a KL2-type Acinetobacter baumannii phage and a screening method therefor, a phage composition and the use, and a drug. The KL2-type Acinetobacter baumannii phage is named AB_SZL2, and is deposited in the China Center for Type Culture Collection with the deposit number CCTCC NO: M20241522; or the KL2-type Acinetobacter baumannii phage is named AB_SZL3, and is deposited in the China Center for Type Culture Collection with the deposit number CCTCC NO: M20241523. The KL2-type Acinetobacter baumannii phage can accurately target KL2-type Acinetobacter baumannii, and has an efficient bactericidal effect, thereby reducing the harm of KL2-type Acinetobacter baumannii and effectively addressing the problem of the antibiotic resistance of KL2-type Acinetobacter baumannii.

The invention provides a pharmaceutical composition, glycyrrhizic acid and polymyxin B self-assembled carrier-free hydrogel as well as a preparation method and application thereof, and belongs to the technical field of biological medicines. The invention provides a pharmaceutical composition. The pharmaceutical composition comprises glycyrrhizic acid and polymyxin B. According to the pharmaceutical composition, the inhibition effect on MRSA is enhanced through drug combination, the use of polymyxin B is reduced through the synergistic effect, and the development pressure of antibiotic drug resistance is relieved. According to the hydrogel formed by crosslinking the glycyrrhizic acid and the calcium chloride, the glycyrrhizic acid and the calcium chloride are crosslinked to form the hydrogel, and the calcium chloride is introduced into a glycyrrhizic acid system to increase the mechanical strength of the glycyrrhizic acid hydrogel, so that the glycyrrhizic acid hydrogel can be better attached to a wound. The invention provides a glycyrrhizic acid and polymyxin B self-assembled carrier-free hydrogel and a preparation method of the glycyrrhizic acid and polymyxin B self-assembled carrier-free hydrogel. The hydrogel does not contain any inert carrier component at all, the drug loading rate of 100% is achieved, and adverse reactions possibly caused by a traditional carrier system are effectively avoided.

Systems and methods for selecting a treatment regimen for a particular patient are provided. The treatment regimen is selected using a first data store including a first plurality of patient records for a first plurality of patients, and a second data store including efficacy rates of a plurality of treatment regimens against a plurality of infections and infection-causing pathogens. The system, or a user of the system, identifies a first infection of the particular patient and a first treatment regimen to be prescribed to treat the first infection. A second plurality of patient records is generated by identifying, in the first plurality of patient records of the first data store, patient records associated with diagnosis or treatment of the first infection. The second plurality of patient records are appended with efficacy rates for the first infection from the second data store. Systems and methods of the present disclosure can use these appended records to generate a dynamic model configured to determine a likelihood estimation that the first treatment regimen is an appropriate treatment regimen to treat the first infection.

The invention belongs to the technical field of microorganisms, and discloses a bacteriophage which comprises a bacteriophage strain M01 with the preservation number of CCTCC M 20251724 or a variant strain of the bacteriophage strain M01. The variant strain and the bacteriophage strain M01 at least have 95% of average nucleotide identity on the genome. The bacteriophage M01 or the variant strain thereof provided by the invention has strong adsorption and lysis effects on aeromonas hydrophila, does not have genes for coding toxin, virulence factor or antibiotic resistance in a genome, and has good temperature stability and acid-base tolerance; the aeromonas hydrophila can be well applied to aquaculture to prevent and / or treat bacterial septicemia and other diseases caused by aeromonas hydrophila infection.

The invention relates to a compound of formula Ia and / or formula Ib: or a pharmaceutically acceptable salt, solvate or prodrug thereof, where the groups are defined herein. The invention also relates to a pharmaceutical formulation comprising the compound for treating or detecting a microbial infection in a subject, a method of determining antimicrobial resistance of a microbial infection using the compound, and a method of determining an effective dose of one or more antimicrobial agents to kill a microorganism using the compound.

It is unequivocal that to facilitate targeted antimicrobial prescribing practices and to help reduce the increasing global burden of antibiotic resistance, there is an urgent need for the development of novel and truly rapid (less than or equal to 1 hour) AST platforms. A 785 nm SERS based methodology is described that results in accurate MIC determinations for all tested strain / antibiotic pairs following a 30 minute drug incubation period. The time for an SERS AST result is -1 hour. The SERS-AST method works for both Gram positive and Gram negative species and for all primary mechanisms of antibiotic activity. Agreement with 24 hour growth determined MICs is obtained for both bactericidal and bacteriostatic antibiotics although different patterns of dose dependent SERS intensities characterize these two types of antibiotics. Bacterial SERS spectra due to secreted purine nucleotide degradation products (principally adenine, guanine, xanthine and hypoxanthine).

The invention discloses mannheimia haemolytica outer membrane vesicles as well as a preparation method and application thereof, and belongs to the technical field of bioengineering. The OMV is separated from Mh-5 strain culture supernatant through tangential flow ultrafiltration combined with an ultracentrifugation technology, and animal experiments prove that a high-level IgG / IgM antibody can be induced by intramuscular injection of 50 micrograms per mouse, expression of inflammatory factors such as IL-6 and TNF-alpha of the spleen is remarkably improved, the protection rate after challenge reaches 85.7%, and pathological damage is remarkably lighter than that of an inactivated vaccine group. According to the scheme provided by the invention, the problems of insufficient serotype coverage and antibiotic resistance in the prior art are solved, and a new strategy is provided for prevention and control of mannheimia haemolytica.

This invention provides a novel nebulization suspension comprising amoxicillin and clavulanate for the effective treatment of pneumonia. The formulation is specifically designed for pulmonary delivery, offering several advantages over traditional oral antibiotics. Key features include mucoadhesive properties that enhance drug retention 5 in the lungs, sustained release characteristics for prolonged therapeutic action, and potential biofilm disruption to combat antibiotic resistance. This localized delivery approach aims to minimize systemic side effects, improve treatment efficacy, and address the growing challenge of antibiotic resistance in pneumonia.

The invention relates to the technical field of probiotic development and utilization, in particular to a goose source Weissella cibaria F11 and application thereof. The Weissella cibarius F11 is preserved in the China General Microbiological Culture Collection Center on July 11, 2025, and the preservation number is CGMCC NO.35211. The Weissella cibarius F11 has the characteristics of good acid resistance and cholate resistance, and can be used for preparing the acid-resistant and cholate-resistant strain. And the bacillus subtilis has a good inhibition effect on pathogenic bacteria such as escherichia coli, pseudomonas aeruginosa, staphylococcus aureus and salmonella typhimurium, and also has stable acid production capacity and good safety. The Weissella sinus F11 provided by the invention meets the probiotic characteristic standard, the antibiotic resistance spectrum of the Weissella sinus F11 meets the feed probiotic safety standard, the growth of goslings can be remarkably promoted, the death rate and diarrhea occurrence rate of the goslings can be remarkably reduced, and the weissella sinus F11 can be used for preparing feed probiotics. The development potential in the fields of preparation of bacteriostatic and antibacterial drugs, probiotics for poultry feed, feed additives, poultry feed and the like is huge.

The invention discloses a traditional Chinese medicine composite lactobacillus acidophilus NM probiotic preparation for improving oral bacterial flora and a preparation process thereof, and relates to the related field of biotechnology. According to the traditional Chinese medicine composite lactobacillus acidophilus NM probiotic preparation, the synergistic effect of probiotics and traditional Chinese medicine is combined, the traditional Chinese medicine composite lactobacillus acidophilus NM probiotic preparation has the multiple advantages of regulating oral flora, resisting bacteria and diminishing inflammation, resisting oxidation, relieving fatigue and the like, lactobacillus acidophilus NM can tolerate acid and cholate, pathogenic bacteria such as escherichia coli, staphylococcus aureus and salmonella are effectively inhibited, and the traditional Chinese medicine composite lactobacillus acidophilus NM probiotic preparation is suitable for oral administration. The traditional Chinese medicine composition has the advantages that the traditional Chinese medicine composition can be used for reducing dental caries, gingivitis and ozostomia, is free of antibiotic drug resistance and is safer after being used for a long time, radix scutellariae, honeysuckle and green tea extracts are rich in flavonoids and tea polyphenols and can further resist bacteria and inflammation and improve oral health, and meanwhile, the probiotics can reduce blood lactic acid, blood urea nitrogen and blood ammonia, enhance SOD, CAT and GSH-Px vitality and inhibit lipid peroxidation, so that body fatigue is relieved, and the traditional Chinese medicine composition can be used for preventing and treating dental caries, gingivitis and ozostomia. The immunity is improved, and preparation forms are diversified.

The invention belongs to the technical field of biomedical materials, and discloses a viola philippica exosome-loaded composite hydrogel as well as a preparation method and application thereof, the composite hydrogel is prepared by mixing methacrylated polylysine (PLMA), oxidized dextran (ODex), viola philippica exosome (V-E), a photoinitiator and a physiologically compatible solvent and performing illumination crosslinking; the preparation method comprises the following steps: respectively preparing PLMA and ODex solutions, extracting and purifying V-E, adding a photo-crosslinking agent (LAP), mixing the components to obtain a precursor liquid, and carrying out in-situ curing molding through ultraviolet-visible light irradiation. The composite hydrogel provided by the invention solves the problems that the existing wound dressing is difficult to fit with irregular wounds, is antibacterial and easy to resist drugs, and lacks active anti-inflammatory and efficient healing promotion capabilities, and is suitable for repair treatment of infectious open wounds such as burns, trauma, diabetic foot ulcer and postoperative infected incisions.

The application discloses a Vibrio harveyi oral vaccine and a preparation method and application thereof. The application uses a lactococcus lactis NZ9000 expression system, modifies transformation parameters, effectively expresses Vibrio harveyi OmpU protein, constructs a lactococcus lactis (NZ9000) engineering bacterium expressing Vibrio harveyi outer membrane protein (OmpU), develops an oral vaccine against Vibrio harveyi infection, aims to reduce the infection of economic animals in seawater aquaculture by oral administration, provides a new scheme for dealing with the harm of Vibrio harveyi infection and antibiotic resistance and the like, promotes the breeding of fry and fingerlings, and promotes the development of biological agriculture and related industries. The strategy is expected to overcome the problems of traditional injection vaccines, such as inconvenient operation and great stress, and can provide a new technical scheme for reducing the dependence of the aquaculture industry on antibiotics and promoting the establishment of a green and healthy breeding mode.

This invention provides a method for monitoring and evaluating the risk of pathogenic bacteria transmission in poultry farm feces, belonging to the field of livestock and poultry biosecurity control technology. The method includes evaluating the risk of Salmonella transmission during the poultry physiological cycle, assessing the risk of antibiotic resistance associated with drug administration behavior, and monitoring the function during composting based on microbial community structure and metabolic function. This invention can accurately locate the highest-risk nodes of pathogen contamination and antibiotic resistance evolution during the breeding cycle, solving the problem of inaccurate identification of risk sources in existing technologies and avoiding poultry product contamination due to missed risk assessments. It overcomes the single-dimensional limitation of existing technologies that only detect the quantity of pathogens, comprehensively evaluating pathogen risk from phenotypic, molecular, and functional levels. The assessment results are more in line with the actual biosecurity needs of poultry farming, ultimately reducing the safety risks of poultry product contamination and the spread of antibiotic resistance.

The invention discloses an antibody as well as a preparation method and application thereof. The antibody has good binding activity with OXA-23 type carbapenem enzyme, and can reduce the carbapenem drug resistance level of the acinetobacter baumannii, so that the clinical use concentration of meropenem is reduced, and the treatment effect of meropenem on the acinetobacter baumannii is improved. In addition, the antibody disclosed by the invention can also inhibit OXA-23 protein secreted by bacteria, prevent the bacteria from hydrolyzing carbapenem antibiotics, increase the concentration of antibiotics in a medication part, and facilitate the removal of mixed infection with acinetobacter baumannii. The invention provides a new strategy for treating acinetobacter baumannii infection, and the application prospect is wide.

This invention discloses a broad-spectrum Staphylococcus aureus bacteriophage, SapYZUbeta, and its applications. This bacteriophage has been deposited at the China Center for Type Culture Collection (CCTCC) on May 16, 2022, with accession number CCTCC NO: M 2022629. Identification revealed that the full-length gene of this bacteriophage is 17,790 bp, and it does not contain tRNAs or genes associated with lysogenicity, virulence, or antibiotic resistance. This genetic background confirms the safety of this bacteriophage for use against foodborne pathogens and for bacteriophage therapy. Furthermore, the bacteriophage exhibits a high titer of 1.9 × 10⁻⁶. 9 The phage, with a concentration of PFU / mL, exhibits stable activity within a pH range of 3–12 and a temperature range of -80–60°C, and can be applied to various matrices. The phage provided by this invention can lyse multidrug-resistant wild-type strains isolated from different regions, including MRSA and MSSA, and is characterized by a broad lysis spectrum and high lysis efficiency.

In some aspects, a system is disclosed for detecting genetic targets for diagnosing tuberculosis and associated antibiotic resistance. The system includes a mechanical instrument and a cartridge assembly. The cartridge assembly comprises one or more reservoirs, with at least one reservoir containing a wet reagent. The cartridge also includes a chip with a fluidic channel holding a liquid slug. The chip has an optical detection region positioned between a heating region and a cool region. The mechanical instrument controls the back and forth motion of the liquid slug between the heating and cool regions. Additionally, the cartridge assembly includes one or more puncture elements configured to pierce the reservoirs and provide the wet reagent to the chip. The system further includes an optical detection unit with an optical light-emitting element, an optical detector, and a processing unit for analyzing the optical detection region of the chip.

Neisseria gonorrhoeae is one of the most common bacterial sexually transmitted infections (STI). Diagnosis depends on standard nucleic acid amplification testing (NAAT), which is impracticable in most low-resource settings, where the prevalence of this STI is highest. Consequently, such areas utilize syndromic management, which misses a high proportion of cases and leads to antibiotic overuse, contributing to the troubling rise of resistance to the commonly prescribed ciprofloxacin, cefixime and ceftriaxone antibiotics for the treatment of N. gonorrhoeae infections. A specific, highly sensitive and cost-effective lateral flow assay is disclosed that utilizes CRISPR-Cas orthologs, multiplex SHERLOCK technology and isothermal amplification via recombinase polymerase amplification (RPA) for the rapid detection of antibiotic resistance to ciprofloxacin, cefixime and / or ceftriaxone at the point of care. This approach has the potential to increase treatment efficacy in the field and mitigate the spread of antibiotic resistance.

The invention discloses an antibiotic resistance prediction method based on a metric element learning architecture. According to the framework, an adaptive mechanism is adopted, and the characteristics of different antibiotics and the distribution characteristics of genome data are precisely matched with an adaptive machine learning model by deeply analyzing the characteristics of the different antibiotics and the distribution characteristics of the genome data. Escherichia coli whole genome sequencing data is adopted, and prediction research is carried out aiming at whether antibiotics have drug resistance or not, so that an optimal prediction model under different drug types and data distribution conditions is evaluated. In addition, molecular structure characteristics and data distribution modes of antibiotics are deeply excavated, and a metrics-based meta learning model matching mechanism is constructed. According to the method, through a metrics-based meta learning framework, the problem of model selection in antibiotic resistance prediction in a complex scene can be effectively solved; meanwhile, in a new drug resistance prediction task, a zero sample learning ability is realized, model adaptation can be completed without extra training data, and the computing resource consumption cost in a model training process is effectively reduced.

The present invention discloses a traditional Chinese medicine compound Lactobacillus acidophilus NM probiotic preparation for improving oral bacterial flora and its preparation process, which relates to the related field of biotechnology. The traditional Chinese medicine compound Lactobacillus acidophilus NM probiotic preparation of the present invention combines the synergistic effects of probiotics and traditional Chinese medicine, and has multiple advantages such as regulating oral flora, antibacterial and anti-inflammatory, antioxidant, and relieving fatigue. Lactobacillus acidophilus NM can tolerate acid and bile salts, effectively inhibit pathogenic bacteria such as Escherichia coli, Staphylococcus aureus, and Salmonella, reduce the occurrence of dental caries, gingivitis, and halitosis. It has no antibiotic resistance and is safer for long-term use. The extracts of Scutellaria baicalensis, honeysuckle, and green tea are rich in flavonoids and tea polyphenols, which can further antibacterial and anti-inflammatory and improve oral health. At the same time, this probiotic can reduce blood lactic acid, blood urea nitrogen, and blood ammonia, enhance the activities of SOD, CAT, and GSH-Px, and inhibit lipid peroxidation, thereby relieving body fatigue and enhancing immunity. The preparation forms are diverse.

This utility model belongs to the technical field of antibiotic-reduced feed production equipment, specifically disclosing a herbal medicine pulverizing device for antibiotic-reduced feed for livestock. It includes a fixed frame, a pulverizing mechanism, and a cooling mechanism, with the pulverizing mechanism fixedly connected to the fixed frame. The pulverizing mechanism includes a pulverizing cylinder and a grinding box arranged sequentially. The pulverizing cylinder has a feed inlet at the upper end and an arc-shaped filter screen at the lower end. A pulverizing roller is rotatably connected inside the pulverizing cylinder. The grinding box has a discharge outlet at the lower end and a grinding roller assembly is rotatably connected inside the grinding box. The cooling mechanism includes a water-cooling jacket, a water pump, a water supply pipe, and a return water pipe. This utility model, by adding a water-cooling jacket to the outside of the pulverizing mechanism and continuously supplying cold water to the water-cooling jacket via a water pump for heat exchange, promptly reduces the temperature in the working cavity of the pulverizing mechanism, preventing excessive temperature accumulation in the working cavity and thus avoiding the heat loss of heat-sensitive active ingredients in the herbal medicine.

The application discloses a traditional Chinese medicine composition for preventing and treating chicken Bordetella, a preparation method and application thereof. The traditional Chinese medicine composition for preventing and treating chicken Bordetella comprises the following raw medicinal materials in parts by weight: one red 15-20 parts, Tianwen grass 15-20 parts, goldenrod 10-15 parts, Jixiang grass 10-15 parts, white yam 5-12 parts, Buddha's hand 5-12 parts and platycodon 5-10 parts. The traditional Chinese medicine composition adopts one red, Tianwen grass, goldenrod, Jixiang grass, white yam, Buddha's hand and platycodon for reasonable compounding, has the effects of clearing heat and cooling blood, relieving cough and asthma, and can effectively treat chicken Bordetella disease. The seven kinds of medicines are mixed to prepare an oral liquid, the seven kinds of medicines have a synergistic effect in the preparation process, the effects of the medicines are effectively exerted, and the effects of clearing heat and detoxifying, clearing heat and cooling blood, relieving cough and asthma are further enhanced. The composition is scientifically matched, has no obvious toxic side reaction and drug tolerance, and can provide a train of thought for solving the problem of antibiotic resistance.

This invention provides a multi-component resource utilization process for black soldier fly larvae larvae slurry, relating to the field of insect resource utilization technology. The process sequentially includes raw material pretreatment, compound enzymatic hydrolysis, lactic acid bacteria fermentation, stratified separation, and targeted treatment of each component. The compound enzymatic hydrolysis uses a combined enzyme system of trypsin and papain, and the lactic acid bacteria fermentation uses *Lactobacillus plantarum*. The fermentation parameters are: carbon-to-nitrogen ratio of 20:1, material-to-liquid ratio of 4:1 (w / v), pH of 6.5, fermentation temperature of 37°C, and fermentation time of 24 hours. This process achieves the synergistic recovery and high-value utilization of all components of black soldier fly larvae. A single process can simultaneously produce four types of products: insect oil, water-soluble fertilizer, antimicrobial peptide additives, and antibiotic-free aquatic feed ingredients, significantly improving resource utilization and industrial added value. The entire process involves no organic solvent addition, employs low-temperature enzyme inactivation to reduce energy consumption, is environmentally friendly and energy-saving, and avoids antibiotic resistance issues.

This invention discloses a strain of *Bacillus saeformis* H1, its culture method, and its applications, relating to the field of microbial technology. The strain was deposited on March 31, 2026, at the China General Microbiological Culture Collection Center (CGMCC), with accession number CGMCC No. 38117. This strain exhibits strong environmental adaptability, can stably grow under neutral to strongly alkaline conditions, and secretes antibacterial substances with low toxicity and no pathogenicity. After optimization, its optimal liquid fermentation conditions are: 5 g / L yeast extract, 10 g / L peptone, 37 g / L sucrose, pH=10, temperature 25℃, rotation speed 140 rpm, and culture time 24 h. The fermentation supernatant of this strain shows significant inhibitory effects on Gram-positive bacteria such as *Staphylococcus aureus*, methicillin-resistant *Staphylococcus aureus*, and *Streptococcus pneumoniae*, and can be prepared into drug sensitivity tablets. The *Bacillus saeformis* H1 provided by this invention can be used to prepare antibacterial drugs or antibacterial infection drugs, providing a new strategy for alleviating the problem of antibiotic resistance.

A process and system for removal of antibiotic compounds from a patient's body can include having a patient digest an antibiotic removal agent or an antibiotic deactivation agent. The agent can include anionic hairy cellulose nanocrystals (AHCNC) hybridized with a resin, such as cholestyramine (CHA). The agent can pass through the patient's digestive system to remove antibiotic compounds that may reside therein as a consequence of an antibacterial treatment provided to the patient. Removal of the antibiotic compounds from the patient's digestive system can avoid evolution of antimicrobial resistance.

The present invention belongs to the technical field of aspergillosis treatment, and specifically discloses the use of carbonyl cyanide-4-trifluoromethoxyphenylhydrazone in the prevention and treatment of Aspergillus fumigatus infection, that is, using it as the sole active ingredient in the preparation of a drug for preventing or treating diseases caused by Aspergillus fumigatus infection, or for the preparation of an antibacterial and / or bactericidal product for Aspergillus fumigatus. The present invention first discovered that carbonyl cyanide-4-trifluoromethoxyphenylhydrazone has a significant inhibitory effect on both wild-type and drug-resistant strains of the human pathogenic fungus Aspergillus fumigatus, and can inhibit its colony growth, hyphal growth, and conidia formation, thereby providing a new therapeutic drug for Aspergillus fumigatus infection. At the same time, it solves the problem of antibiotic resistance that plagues the clinical treatment of Aspergillus fumigatus infection, and can circumvent the disadvantage that antibiotics are prone to drug resistance.

The application discloses a kind of low-toxicity broad-spectrum antibacterial peptide with WW as symmetry center, the antibacterial peptide is that WK is repeated twice and symmetrically distributed in two sides, and WW is used as symmetry center, obtain antibacterial peptide WKWKWWKWKW-NH2 (N2W2), then the tryptophan of C terminal and N terminal of N2W2 is replaced by leucine and / or isoleucine;The antibacterial peptide can basically maintain the excellent antibacterial activity of parent peptide, and their hemolytic activity is greatly reduced, and the safety is improved. The antibacterial activity of IL-N2W2 is highest, but the stability needs to be improved, so D-type amino acid replacement is carried out on IL-N2W2 to obtain D-IL-N2W2. D-IL-N2W2 maintains the high antibacterial activity and low toxicity of IL-N2W2, and can still completely inhibit bacterial growth after incubation with high-concentration trypsin or chymotrypsin, has very great potential in relieving antibiotic resistance, and has good application prospect in preparing clinical antibacterial drugs.

The application discloses application of bio-organic acid in preparation of plasmid conjugation transfer inhibitor and / or antibacterial drugs. The bio-organic acid in the application includes one or more of citric acid, fumaric acid or alpha-ketoglutaric acid. The application finds the possibility of the bio-organic acid as the conjugation transfer inhibitor in preventing and controlling the spread of antibiotic resistance level through in-vivo and in-vitro conjugation tests. The application provides the use of the bio-organic acid as the conjugation transfer inhibitor, limits the conjugation transfer of various clinical drug-resistant plasmids, and is one of strategies for solving the problem of bacterial drug resistance.

The invention provides a calcium sulfate hemihydrate composite material with an antibacterial property, a preparation method of the calcium sulfate hemihydrate composite material and application of the calcium sulfate hemihydrate composite material in antibacterial bone repair. The preparation method comprises the following steps: firstly, selecting a polymer with good biocompatibility to be crosslinked with phthalocyanine, and then coating the surface of calcium sulfate hemihydrate with a phthalocyanine-polymer in a coordination manner through an in-situ synthesis method, so as to synthesize the calcium sulfate hemihydrate osteogenic material with uniform micron-sized granularity. According to the phthalocyanine-polymer-calcium sulfate hemihydrate composite material disclosed by the invention, the problems of drug resistance and toxic and side effects of antibiotics are solved through photodynamic and photo-thermal combined antibacterial properties; the defects that calcium sulfate hemihydrate is easy to absorb moisture and cannot ensure the bone repair performance are avoided through polymer coating; through the tissue scaffold effect of the polymer, adhesion and proliferation of new bone cells are facilitated, and the bone repair survival rate is greatly increased; moreover, through an in-situ synthesis method, the granularity of the calcium sulfate hemihydrate is effectively controlled, and the plasticity of the bone cement is ensured.